Lv11
30 积分 2023-03-04 加入
Cracking the Genomic Code of CDK4/6 Inhibitor Resistance
6小时前
待确认
Pharmacologic restoration of GTP hydrolysis by mutant RAS
21天前
已完结
Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers
1个月前
已完结
Targeting cancer with small molecule pan-KRAS degraders
2个月前
已完结
CDK4/6 Inhibitor Efficacy in ESR1 -Mutant Metastatic Breast Cancer
2个月前
已完结
Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− metastatic breast cancer?
2个月前
已完结
Rational combinations of targeted cancer therapies: background, advances and challenges
3个月前
已完结
Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC
3个月前
已完结
Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC
3个月前
已完结
Inhibition of CDK7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy
4个月前
已完结
皖公网安备34019202002308
